Chronic Idiopathic Urticaria Clinical Trial
Official title:
A Randomized, Multicenter, Double-Blind, 4-Arm, Parallel-Group, Active Controlled, Phase 3 Study to Compare Efficacy, Safety and Immunogenicity of ADL-018 150 mg and 300 mg With US-Licensed Xolair® 150 mg and 300 mg Administered Through Subcutaneous Route Every 4 Weeks in Patients With Chronic Idiopathic Urticaria (CIU) Who Remained Symptomatic Despite Treatment With Approved Doses of H1 Antihistamines
The purpose of the study is to compare the efficacy, safety, tolerability, and immunogenicity of ADL-018 compared to XOLAIR in patients with Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) who remain symptomatic on H1 antihistamine treatment
Status | Recruiting |
Enrollment | 600 |
Est. completion date | April 3, 2025 |
Est. primary completion date | December 31, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: 1. Capable of providing written informed consent, adhering to all visit schedules, and meeting study requirements. 2. Male or female patients 18 to 75 years of age (both inclusive) at the time of screening. 3. Diagnosis of CIU refractory to H1 antihistamines at the time of randomization, as defined by all of the following: - CIU diagnosis for at least 6 months. - Must have been on an approved H1 antihistamine for CIU for at least 3 consecutive days immediately prior to the Day -14 screening visit and must document current use on the day of initial screening. - Presence of itch and hives for = 8 consecutive weeks at any time prior to enrollment despite current use of H1 antihistamine treatment. - In-clinic UAS = 4 on at least 1 of the screening visit days (Day -14, Day -7, or Day 1). - UAS7 (range 0-42) = 16 and itch component of UAS7 (range 0-21) = 8 during 7 days prior to randomization. 4. Willing and able to complete a daily symptom diary for the duration of the study and must not have any missing diary entries in the 7 days prior to randomization. 5. Females of childbearing potential must be willing to use acceptable contraceptive methods throughout the study and for 6 months thereafter. 6. Females of non-childbearing potential must have undergone sterilization procedures, at least 6 months prior to the first dose or be postmenopausal with amenorrhea for at least 1 year prior to the first dose and follicle stimulating hormone serum levels consistent with postmenopausal status. Exclusion Criteria: 1. Participation in a clinical trial involving the administration of an investigational drug or marketed drug within 30 days prior to initial dosing (90 days for biologics). 2. Clearly defined underlying etiology for chronic urticarias other than CIU. 3. Evidence of parasitic infection. 4. Atopic dermatitis, bullous pemphigoid, dermatitis herpetiformis, senile pruritus, or any other skin disease associated with itch. 5. Previous treatment with omalizumab within a year prior to screening. 6. Routine doses of the following medications within 10 days prior to screening: Systemic or cutaneous (topical) corticosteroids (prescription or over the counter), hydroxychloroquine, methotrexate, cyclosporine, or cyclophosphamide or investigational agents such as benralizumab or dupilumab etc. 7. IVIG ( Intravenous immune globulin) or plasmapheresis within 90 days prior to screening. 8. Regular (daily/every other day) doxepin (oral) use within 14 days prior to screening. 9. Any H2 antihistamine use within 7 days prior to screening. 10. Any LTRA (Leukotriene receptor antagonists such as montelukast or zafirlukast) within 10 to 14 days prior to screening. 11. Patients with current malignancy, history of malignancy, or currently under work-up for suspected malignancy except non-melanoma skin cancer that has been treated or excised and is considered resolved. 12. Hypersensitivity to omalizumab or any component of the formulation. 13. History of anaphylactic shock. 14. Presence of clinically significant cardiovascular, neurological, psychiatric, metabolic, or other pathological conditions that could interfere with the interpretation of the study results and/or compromise the safety of the patients. 15. Medical examination or laboratory findings that suggest the possibility of decompensation of co-existing conditions for the duration of the study. 16. Evidence of current drug or alcohol abuse. 17. Positive test for hepatitis B, hepatitis C, or HIV. 18. Females with positive pregnancy tests at screening or any other visit. 19. Females who are breastfeeding or lactating. 20. History of any clinically significant disease or condition that, in the opinion of the Principal Investigator (PI)/designee, would render them unsuitable for inclusion in the study. |
Country | Name | City | State |
---|---|---|---|
Jordan | Al Essra Hospital | Amman | |
United States | True Blue Clinical Research | Brandon | Florida |
United States | Access Research Institute | Brooksville | Florida |
United States | San Marcus research Clinic, Inc | Miami Lakes | Florida |
United States | Options Research Group | West Lafayette | Indiana |
Lead Sponsor | Collaborator |
---|---|
Kashiv BioSciences, LLC | COD Research Private Ltd |
United States, Jordan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from baseline in the ISS7 at Week 12 between ADL-018 300 mg and XOLAIR 300 mg | ISS 7 is a weekly itch severity score calculated as sum of the daily itch severity score for 7 days, on a scale of 0 to 3 (0=none to 3=intense/severe) | Change from Baseline at week 12 | |
Primary | Relative potency of ADL-018 and XOLAIR | Relative potency ADL-018 to the Xolair defined as the dose of ADL-018 that produces the same biological response as one unit of the dose of the Xolair.
The relative potency and its CI will be measured by change in ISS7 at Week 12 using a 4 point assay based on the 300 mg and 150 mg dose levels of each product. |
Change from Baseline at week 12 | |
Secondary | Change from baseline in the ISS7 at Week 2, 4, 6, 8, 16, 20, and 24 | ISS 7 is a weekly itch severity score calculated as sum of the daily itch severity score for 7 days, on a scale of 0 to 3 (0=none to 3=intense/severe). | Change from Baseline at Week 2, 4, 6, 8, 16, 20, and 24 | |
Secondary | Change from baseline in UAS7 at Weeks 2, 4, 6, 8, 12, 16, 20, and 24 | Change from baseline in the Urticaria Activity Score (UAS) - sum of the daily number of wheals score and itch severity score over 7 days, range from 0 (minimum) to 6 (maximum) | Change from Baseline at Weeks 2, 4, 6, 8, 12, 16, 20, and 24 | |
Secondary | Change from baseline in weekly number of hives (urticaria) score (HSS7) at Weeks 2, 4, 6, 8, 12, 16, 20, and 24 | Change from baseline in the weekly number of wheals score at Week 12 | Change from Baseline at Weeks 2, 4, 6, 8, 12, 16, 20, and 24. | |
Secondary | Percentage of patients with angioedema-free days from Week 4 to Week 12 | Percentage of angioedema-free days from Week 4 to Week 12 | change from Week 4 to Week 12 | |
Secondary | Percentage of complete responders (UAS7=0) at Week 12 | Percentage of complete responders with weekly Urticaria Activity Score =0 at Week 12 | change from baseline at week 12 | |
Secondary | Percentage of patients achieving UAS7 = 6 at Weeks 2, 4, 6, 8, 12, 16, 20, and 24 | Percentage of patients with a weekly Urticaria Activity Score =6 | Change from Baseline at Weeks 2, 4, 6, 8, 12, 16, 20, and 24 | |
Secondary | Change from baseline in the overall Dermatology Life Quality Index (DLQI) score at weeks 4, 8, 12, 16, 20, and 24. | Change from baseline in the overall dermatology life quality index (DLQI) score at Week 12; comparisons of ADL-018 and XOLAIR treatment arms. The DLQI consists of 10 questions concerning patients' perception of the impact of skin diseases on different aspects of their health-related quality of life over the last week. The DLQI is calculated by adding the score of each question, resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired | Change from Baseline at Week 12 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02814630 -
Three-month, Single-center Study to Identify Biomarkers/Response to Xolair Therapy in Chronic Idiopathic Urticaria
|
N/A | |
Completed |
NCT01803763 -
Prospective Double-blind Placebo-controlled Study of the Effect of Xolair (Omalizumab) in Chronic Urticaria Patients
|
Phase 2/Phase 3 | |
Completed |
NCT00536380 -
Study for the Treatment of Chronic Idiopathic Urticaria With High Doses of AERIUS (Desloratadine) (Study P04849)
|
Phase 4 | |
Completed |
NCT03183024 -
Treatment of Chronic Urticarial Unresponsive to H1-antihistamines With an Anti-IL5Ralpha Monoclonal Antibody
|
Phase 4 | |
Completed |
NCT00757562 -
Safety of Desloratadine in Children With Allergy Sensitivity and Chronic Hives, Who Are Poor Metabolizers of Desloratadine (Study P02994)
|
Phase 3 | |
Completed |
NCT03858634 -
A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic Diseases
|
Phase 2 | |
Completed |
NCT01292473 -
A Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1)
|
Phase 3 | |
Completed |
NCT00866788 -
A Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic With Antihistamine Treatment (H1)
|
Phase 2 | |
Recruiting |
NCT01635127 -
Efficacy Study of Canakinumab to Treat Urticaria
|
Phase 2 | |
Recruiting |
NCT05936567 -
Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria
|
Phase 2 | |
Not yet recruiting |
NCT02166151 -
Efficacy and Safety of Omalizumab in Chronic Idiopathic Urticaria
|
Phase 3 | |
Recruiting |
NCT02031679 -
Efficacy and Safety of CRTH2 Antagonist AZD1981 in Chronic Idiopathic Urticaria (CIU) Antihistamines
|
Phase 2 | |
Recruiting |
NCT00346606 -
The Efficacy and Safety of Desloratadine With Levocetirizine in Treatment of Chronic Idiopathic Urticaria
|
Phase 4 | |
Completed |
NCT01264939 -
A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists
|
Phase 3 | |
Completed |
NCT01287117 -
A Study of the Efficacy and Safety of Omalizumab (Xolair) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine (H1) Treatment
|
Phase 3 | |
Completed |
NCT03406325 -
Mast Cell Activation Test in Allergic Disease
|
||
Not yet recruiting |
NCT04175704 -
Evaluating the Safety and Tolerability and Determining the PK and PD of Single Dose UB-221 in Chronic Spontaneous Urticaria
|
Phase 1 | |
Withdrawn |
NCT01030120 -
Etanercept for the Treatment of Chronic Urticaria
|
Phase 2/Phase 3 | |
Completed |
NCT00264303 -
CUTE (Chronic Urticaria Treatment Evaluation)
|
Phase 4 | |
Completed |
NCT01599637 -
Mode of Action Study of Omalizumab in Patients With Chronic Idiopathic Urticaria (CIU) Who Fail to Respond to Antihistamine Treatment
|
Phase 2 |